Clinical Trials Logo

Clinical Trial Summary

Small vessel disease (SVD) accounts for 25% of strokes and is the second most common cause of dementia after Alzheimer's disease. Unlike other causes of stroke, SVD manifests itself years before the stroke by the accumulation of tissue damage. Although heterogeneous, these lesions appear on Magnetic Resonance Imaging (MRI) as white matter hypersignals (WMH). In this context, the ANR SUMMIT project will characterize these lesions in vivo to develop new markers in the early stages of stroke. It is subdivided into 4 work packages, the third one being promoted by CHRU de Tours.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06159140
Study type Interventional
Source University Hospital, Tours
Contact Jean Philippe COTTIER, PHD
Phone +332 18 37 06 73
Email jean-philippe.cottier@univ-tours.fr
Status Recruiting
Phase N/A
Start date March 26, 2024
Completion date March 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05300997 - Translational Immunodiagnostics in Stroke (TrImS)
Recruiting NCT03625830 - The Efficacy and Safety of SeQuent® Please in the Treatment of Small Vessel Disease (SVD) Patient N/A